The Quantellect read.As of Nov 19, 2026, 3 active firms cover Cytek Biosciences Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $4.75 to $5.50, so the covering firms are broadly aligned. The average target of $5.08 sits 14% below the current $5.94. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.08
-14.4% downside
Average target across 3 active firms as of Nov 19, 2026 vs $5.94 current
Highest Target$5.50
Average Target$5.08
Lowest Target$4.75
Detailed analyst forecasts for CTKB
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate CTKB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CTKB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.10 – $-0.06 · 2 analysts · -47% YoY
Next period, 2 analysts expect Cytek Biosciences Inc to earn $-0.08 a share (range $-0.10 – $-0.06), versus $-0.15 a year earlier. Full-year consensus is $-0.29, growing to $-0.18 the year after.
REVENUE · NEXT QUARTER
$47.6M
Range $47.0M – $48.3M · 2 analysts · +8% YoY
Revenue is expected to reach $47.6M (range $47.0M – $48.3M), +7.7% year-over-year. Full-year consensus is $209.2M, rising to $222.8M next year.
Top analysts covering Cytek Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTKB.
#1
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$4.75-20.0% to target
Overall win rate
40%
+ Follow
#2
David Westenberg
Piper Sandler · Rank #314
Buy
$7.50+26.3% to target
Overall win rate
35%
+ Follow
#3
Matthew Sykes
Goldman Sachs · Rank #352
Sell
$3.00-49.5% to target
Overall win rate
38%
+ Follow
#4
TS
Tejas Savant
Morgan Stanley
Neutral
$5.50-7.4% to target
Coverage
—
+ Follow
#5
BS
Brendan Smith
TD Cowen
Buy
$5.00-15.8% to target
Coverage
—
+ Follow
CTKB stock forecast FAQ
What is CTKB's average 12-month price target?+
The 3 active firms with a live target average $5.08 for Cytek Biosciences Inc over the next 12 months, ranging from a $5.50 high to a $4.75 low, as of Nov 19, 2026.
Is CTKB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CTKB?+
The Street-high target is $5.50 (Morgan Stanley), and the Street-low is $4.75 (Stephens & Co.). The average of all 3 active-firm targets is $5.08.
How many active Wall Street firms cover CTKB?+
3 active firms have a recognized rating on Cytek Biosciences Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CTKB?+
Among analysts who currently cover CTKB, Mason Carrico of Stephens & Co. has the strongest overall Quantellect track record (Rank #178). Their current call is Buy with a $4.75 target.
What is Cytek Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.10 – $-0.06) across 2 analysts. Full-year EPS is projected at $-0.29, rising to $-0.18 the following year.
How much revenue is Cytek Biosciences Inc expected to report next quarter?+
Consensus revenue is $47.6M (range $47.0M – $48.3M). Full-year revenue is projected at $209.2M, growing to $222.8M next year.
Have analysts been upgrading or downgrading CTKB lately?+
As of Nov 19, 2026, 2 of 3 active firms rate CTKB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTKB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.